[Corticosteroid effect and vasoconstriction. 2. Influencing the antipsoriatic corticosteroid effect by suppression of vasoconstriction].
D000305:Adrenal Cortex Hormones / Q000494:pharmacology*; D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D005446:Fluocinolone Acetonide / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D006097:Granulation Tissue / Q000187:drug effects / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy / Q000473:pathology; D013997:Time Factors; D014043:Tolazoline / Q000009:adverse effects / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology
D000305:Adrenal Cortex Hormones; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D005446:Fluocinolone Acetonide; D014043:Tolazoline
Kortikosteroideffekt und Vasokonstriktion. 2. Zur Beeinflussbarkeit des antipsoriatischen Kortikosteroideffekts durch Aufhebung der Vasokonstriktion.